Filing summary
Entity and period: The source filing is Access Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2014. This does not match the requested company, Abeona Therapeutics Inc.; verify the filing identity before relying on this summary.
Business context and reporting period
Access was an emerging biopharmaceutical company developing drug-delivery technologies and product candidates. Its marketed product was MuGard for oral mucositis, licensed in the United States to AMAG, with China commercialization and a new South Korean license to Hanmi announced in March 2014. The company was seeking partners for other products and platforms.
Financial performance and position
- Revenue: $208,000 in Q1 2014, down from $1.224 million in Q1 2013. Q1 2014 comprised $146,000 of license revenue and $62,000 of royalties; there were no direct product sales. Q1 2013 included $1.162 million in MuGard product sales.
- Expenses and earnings: Operating expenses were $1.536 million, down from $1.727 million. Operating loss was $1.328 million versus $503,000. Net loss was $859,000; after $725,000 in preferred dividends, loss allocable to common stockholders was $1.584 million, or $0.06 per share. Q1 2013 had net income allocable to common stockholders of $3.354 million, or $0.14 basic earnings per share.
- Key non-operating items: Q1 2014 included a $583,000 gain from revaluing the preferred-stock derivative liability, versus a $4.780 million gain in Q1 2013. The 2013 period also included a $247,000 warrant derivative loss and higher miscellaneous income from platinum inventory sales. Q1 2014 stock-based compensation was $795,000, compared with $77,000 a year earlier.
- Cash flow and liquidity: Operating cash use was $125,000, compared with $346,000 in Q1 2013. Cash declined from $424,000 at year-end to $299,000 at March 31, 2014. Working capital deficit was $9.604 million, up $1.218 million from December 31, 2013.
- Liabilities and equity: Total liabilities were $15.971 million, including $7.510 million of accrued preferred dividends, $857,000 of liquidated damages related to an outstanding registration obligation, and a $607,000 preferred-stock derivative liability. Stockholders’ deficit was $15.493 million. The filing reports no conventional debt balance in the supplied balance-sheet details.
Material changes versus Q1 2013
- Revenue fell sharply as MuGard sales shifted from direct sales to AMAG royalties after the 2013 U.S. license; licensing and royalty revenue together were $208,000 in Q1 2014.
- Lower R&D spending and reduced MuGard selling costs helped reduce total operating expenses, but operating loss widened because revenue was substantially lower.
- The common-stockholder result swung from income to loss, largely reflecting the much smaller preferred-stock derivative revaluation gain in 2014 and the disappearance of prior-year product sales and miscellaneous income.
- Cash fell by $125,000 during the quarter, while the working-capital deficit increased. The company issued 225,000 common shares to employees and granted 10.5 million options in Q1 2014.
Outlook, risks, and contingencies
- Management expected cash, MuGard royalties, and anticipated license receipts to support the current operating level into the first quarter of 2015, while also stating that additional funding would be required to continue operations. The filing cautions that the funding outlook could change and that financing or licensing may not be obtained.
- The company had a history of losses, an accumulated deficit of $268.005 million, and a substantial working-capital deficit. Its 2013 auditor’s report expressed substantial doubt about its ability to continue as a going concern.
- Management expected losses for several years and could not assure sustained profitability. Potential equity financing could dilute existing shareholders.
- A material weakness in internal control over financial reporting remained unremediated, principally due to limited accounting staff and insufficient segregation of duties. Management said disclosure controls were not effective.
- A former Genaera shareholder’s appeal remained pending after the district court dismissed claims against the company and other Access defendants. The company said it intended to contest the claims; it reported no other material pending legal proceedings.
- Preferred-stock dividends continued to accrue, and the filing reported $7.510 million payable at quarter-end. Failure to meet registration-statement obligations had also resulted in $857,000 of accrued liquidated damages.
Important facts for investors to verify
- Confirm that Access Pharmaceuticals—not Abeona Therapeutics—is the intended issuer and that the quarter and filing are correct.
- Review the full financial statements and notes for the nature and terms of preferred securities, derivative valuation assumptions, dividend obligations, and registration-related damages.
- Verify the timing and amount of expected license receipts, royalties, and any Hanmi upfront payment; the supplied filing text does not provide a clear amount for the Hanmi fee.
- Assess available financing, dilution exposure, and the potential share impact of outstanding convertible preferred stock, warrants, and options.
- Check subsequent developments in the pending appeal, internal-control remediation, and the company’s ability to meet its stated funding outlook.